Results for signifikantne translation from Slovenian to English

klinično signifikantne interakcije niso opažene.
no clinically significant interaction is observed.

ti rezultati v okviru hierarhije testiranja za posamezne študije niso veljali za statistično signifikantne.
these results were not considered statistically significant within the framework of the testing hierarchy for the individual studies.

vendar pa in vitro funkcijski testi granulocitov po dodatku sulezomaba niso pokazali signifikantne spremembe.
however, in vitro granulocyte function tests did not show significant changes when the sulesomab was added.

analiza podlestvic lestvice twstrs je pokazala signifikantne učinke na hudost cervikalne distonije ter z njo povezane bolečine in invalidnosti.
analysis of the twstrs sub scales revealed significant effects on the severity of cervical dystonia and its associated pain and disability.

v teh študijah pri bolnikih, zdravljenih z metilnaltreksonijevim bromidom, ni bilo signifikantne povezave med izhodiščnim odmerkom opioida in laksacijskim odzivom.
there was no significant relationship between baseline opioid dose and laxation response in methylnaltrexone bromide-treated patients in these studies.

pri zdravih prostovoljcih do odmerka 800 mg ni signifikantne inhibicije cox- 1 (ocenjene kot ex vivo inhibicija tromboksana b2).
there is no significant inhibition of cox-1 (assessed as ex vivo inhibition of thromboxane b2) up to 800 mg in healthy volunteers.

h-1 in h-2 blokatorji) pred začetkom zdravljenja z zdravilom palladia, v izogib ali zmanjšanje klinično signifikantne degranulacije mastocitov in posledično možnih resnih sistemskih stranskih učinkov.
if systemic mastocytosis is present, standard pre-emptive care (e.g., h-1 and h-2 blockers) should be implemented prior to initiation of palladia to avoid or minimize clinically significant mast cell degranulation and subsequent potentially severe systemic side effects.

a na osnovi modela stratificiranih proporcionalnih ogroženosti. b p-vrednost na osnovi testa log-rank, stratificiranega gleda na predhodno vzdrževalno zdravljenje in linije zdravljenja; ustrezna o’brien-flemingova mejna vrednost signifikantne učinkovitosti je 0,0408.
a derived from a stratified proportional hazards model. b p-value is derived from a log-rank test stratified by prior maintenance therapy and line of therapy; the corresponding o’brien-fleming efficacy boundary significance level is 0.0408.